Session » Vasculitis IV: Diagnosis and Assessment of Disease Activity
- 9:00AM-10:30AM
-
Abstract Number: 3184
Antiphospoholipid Antibodies in Giant Cell Arteritis. What Can They Tell Us?
- 9:00AM-10:30AM
-
Abstract Number: 3182
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
- 9:00AM-10:30AM
-
Abstract Number: 3179
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- 9:00AM-10:30AM
-
Abstract Number: 3181
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis
- 9:00AM-10:30AM
-
Abstract Number: 3183
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
- 9:00AM-10:30AM
-
Abstract Number: 3180
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis